

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奥赛图(北京)医药科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

POLL RESULTS OF THE 2023 ANNUAL GENERAL MEETING HELD ON MAY 28, 2024

References are made to the notice (the “**Notice**”) and the circular (the “**Circular**”) of the AGM both dated April 26, 2024 of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the “**Company**”). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Notice and the Circular.

The AGM was held with the combination of a physical meeting at the conference room of 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, PRC and a virtual meeting online on Tuesday, May 28, 2024 at 10:00 a.m.. The AGM was held in accordance with the requirements of the PRC Company Law and the Articles.

As at the date of the AGM, the total number of issued shares of the Company was 399,398,420, including 110,781,920 H Shares and 288,616,500 Domestic and Unlisted Shares, all of which entitled the Shareholders to attend the AGM and vote for or against or abstain from voting on the resolutions (the “**Resolutions**”) proposed at the AGM. A total of 13 Shareholders and their proxies holding an aggregate of 319,227,900 voting Shares, representing approximately 79.93% of the total number of voting Shares, attended the AGM. Dr. Shen Yuelei, the chairman of the Company, acted as the chairman of the AGM and presided over it. All the Directors, the Supervisors, as well as the secretary of the Board were present at the meeting either in person or by means of telecommunication.

Pursuant to the Listing Rules and as advised by the Company's PRC legal advisors, Dr. Shen Yuelei and Dr. Ni Jian and their controlled corporations (Note 1), collectively holding 16,854,300 H Shares and 93,240,540 Domestic and Unlisted Shares, were required to, and had abstained from voting on the resolution numbered 11 at the AGM. In addition, (i) State Development & Investment Group Co., Ltd. (“**SDIC**”) and its controlled corporations (Note 2), collectively holding 72,937,440 Domestic and Unlisted Shares; (ii) China Merchants Bank Co., Ltd. (“**CMBC**”) and

its controlled corporations (Note 3), collectively holding 26,088,480 H Shares and 51,171,840 Domestic and Unlisted Shares; (iii) China Life Chengda (Shanghai) Healthcare Industry Equity Investment Center (Limited Partnership), holding 14,296,320 Domestic and Unlisted Shares; (iv) Jiangsu China Life Jiequan Equity Investment Center (Limited Partnership), holding 9,222,840 Domestic and Unlisted Shares; (v) PICC Beijing Health Care Fund, L.P., holding 9,222,840 Domestic and Unlisted Shares; (vi) Shenzhen Zhaoyin Gongying Equity Investment Partnership (Limited Partnership), holding 1,355,760 Domestic and Unlisted Shares; (vii) Zhuhai Growth Win-Win Venture Capital Fund (Limited Partnership), holding 2,459,520 Domestic and Unlisted Shares; and (viii) Beijing Yuanqing Bencao Equity Investment Center (Limited Partnership), holding 9,193,680 Domestic and Unlisted Shares are investors of a related party contemplated under the resolution numbered 11, such parties had abstained from voting on the resolution numbered 11 at the AGM as advised by the Company's PRC legal advisors. Accordingly, the total number of Shares entitling the Shareholders to attend and vote on the resolution numbered 11 and other resolutions proposed at the AGM were 93,354,860 and 399,398,420 respectively. The total number of Shares with voting right, on the resolution numbered 11 and other resolutions, represented by the Shareholders attending the AGM in person or by proxy was 39,272,820 and 319,227,900 representing approximately 42.07% and 79.94% of the total number of Share with voting rights, respectively.

Save as disclosed above, to the best of the Directors' knowledge, information and belief, no Shareholders were required to abstain from voting on any of the Resolutions in accordance with the requirements of the Listing Rules. There were no Shares entitling the holder(s) to attend the AGM but abstain from voting in favour of any of the Resolutions under rule 13.40 of the Listing Rules. None of the Shareholders had stated his/her/its intention to vote against or to abstain from voting on any of the Resolutions. The Company was not aware of any Shareholders indicating their intention to vote against any of the Resolutions or abstain from voting at the AGM. All Resolutions were put to vote by way of poll.

Note 1: Shanghai Baiao Evergreen Technology Development Center (Limited Partnership)* (上海百奧常青科技發展中心(有限合夥)), previously known as Beijing Baiao Evergreen Technology Development Center (Limited Partnership)* (北京百奧常青科技發展中心(有限合夥)), Beijing Baiao Changsheng Technology Development Center (Limited Partnership)* (北京百奧常盛科技發展中心(有限合夥)), Beijing Eucure Evergreen Technology Development Center (Limited Partnership)* (北京祐和常青科技發展中心(有限合夥)) and Shanghai Eucure Changsheng Technology Development Center (Limited Partnership)* (上海祐和常盛科技發展中心(有限合夥)), previous known as Beijing Eucure Changsheng Technology Development Center (Limited Partnership)* (北京祐和常盛科技發展中心(有限合夥)).

Note 2: State Development & Investment Corporation (SDIC) VC Fund (Ningbo) of Technology Transfer and Commercialization (Limited Partnership), State Development & Investment Corporation (SDIC) VC Fund (Shanghai) of Technology Transfer and Commercialization (Limited Partnership) and State Development & Investment Corporation (SDIC) Gaoxin (Shenzhen) VC Fund (Limited Partnership).

Note 3: Astral Eminent Limited, Zhaoyin Chengzhang Qihao Investment (Shenzhen) Partnership (Limited Partnership) (招銀成長柒號投資(深圳)合夥企業(有限合夥)), Shenzhen Zhaoyin Langyao Growth Equity Investment Fund Partnership (L.P.) (深圳市招銀朗曜成長股權投資基金合夥企業(有限合夥)), Shenzhen Zhaoyin Chengzhang Shijiuhao Equity Investment Fund Partnership (Limited Partnership) (深圳市招銀成長拾玖號股權投資基金合夥企業(有限合夥)) and CMB International Capital Management (Shenzhen) Co., Ltd. (招銀國際資本管理(深圳)有限公司).

Tricor Investor Services Limited, the Company's H share registrar, two representatives from the Company's Shareholders and one Supervisor, were appointed as the scrutineer at the AGM for the purpose of vote-taking. The poll results in respect of the Resolutions proposed at the AGM were as follows:

ORDINARY RESOLUTIONS		No. of Votes (%)		
		For	Against	Abstain
1.	To receive, consider and approve the 2023 annual report	319,227,900 (100.00%)	0 (0.00%)	0 (0.00%)
2.	To receive, consider and approve audited financial statements for 2023	319,227,900 (100.00%)	0 (0.00%)	0 (0.00%)
3.	To receive, consider and approve the work report of the Board for 2023	319,227,900 (100.00%)	0 (0.00%)	0 (0.00%)
4.	To receive, consider and approve the work report of the Supervisory Committee for 2023	319,227,900 (100.00%)	0 (0.00%)	0 (0.00%)
5.	To receive, consider and approve the final accounts report for 2023	319,227,900 (100.00%)	0 (0.00%)	0 (0.00%)
6.	To consider and approve the proposed re-appointment of KPMG, Certified Public Accountants as the auditor of the Company for 2024 and authorize the Board to fix its remuneration	319,227,900 (100.00%)	0 (0.00%)	0 (0.00%)
7.	To consider and approve the proposed remuneration of Directors for 2024	319,227,900 (100.00%)	0 (0.00%)	0 (0.00%)
8.	To consider and approve the proposed remuneration of Supervisors for 2024	319,227,900 (100.00%)	0 (0.00%)	0 (0.00%)
9.	To consider and approve the proposed 2023 profit distribution plan	319,227,900 (100.00%)	0 (0.00%)	0 (0.00%)
10.	To review, consider and approve the proposed annual financial budget for 2024	319,227,900 (100.00%)	0 (0.00%)	0 (0.00%)
11.	To consider and approve confirmation of the Company's related party transactions in 2023 and estimated daily related party transactions in 2024	39,272,820 (100.00%)	0 (0.00%)	0 (0.00%)
12.	To consider and approve the proposed guarantee for bank credit facilities for the Company and subsidiaries	319,227,900 (100.00%)	0 (0.00%)	0 (0.00%)

As more than 50% of votes were casted in favour of each of the above ordinary Resolutions, all of the above Resolutions were duly passed at the AGM.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
*Chairman of the Board, Chief Executive Officer and
Executive Director*

Hong Kong, May 28, 2024

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.